Biotech Millennium found that by clearly defining workflows and implementing a highly configurable notebook, it could move its entire discovery organization to a single ELN system.
Companies that utilize chemicals in their labs and their manufacturing processes must manage those chemicals in a safe environment in accordance with government regulations. At a minimum, to ensure that this is accomplished, a system for managing information about the chemical safety and inventory data should be established and maintained. Best practices, on the other hand, take this minimum and leverage the management of the chemical inventory by taking full advantage of the people, processes, and technology involved. This white paper delves into the best practices involved in managing chemical inventory to achieve the most effective, holistic chemical inventory system.
This white paper examines the challenges of managing research data today and what to look for in an ELN. The white paper also addresses key issues in selecting and deploying an ELN in today’s digital research environment including the importance of seamlessly integrating ELNs with existing research workflows. The white paper concludes with a brief consideration of ELN costs, financial benefits and return on investment (ROI).
Today’s biotech and pharmaceutical production facilities must drive faster times to market and greater profitability for new products by boosting production yields and accelerating commercialization and scaling of capacity.
The short tips in this white paper are intended as a guide to selecting tools which will help you to save valuable time in the eight-phase model of the value creation process.
In this case Astrix supported a leading global pharmaceutical, biopharmaceutical, and medical device contract research organization (CRO) in a major effort to select a commercial LIMS system that would meet their requirements
As the complexity of the global R&D environment has grown over the last several decades, biopharma companies have found it increasingly difficult to accomplish scalable growth with their in-house team alone. This has led to the practice of outsourcing becoming commonplace as a way to reduce costs.
Major research institutions and academic centers operate in an increasingly complex global network of scientific collaborators. In recent years, there has been a rising number of partnerships between non-profit research institutes and pharma, driven by cuts to academic research budgets, waning pipelines, and the pharma industry’s emphasis on open innovation. In mid-2015, for example, GSK teamed up with the University of North Carolina at Chapel Hill to form a research institute and a company dedicated to finding a cure for HIV and AIDS.
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has commenced dosing of patients in ASPIRO, a Phase 1/2 clinical trial of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM)